In-Vivo Patient-Specific Optimization of Transcatheter-Edge-to-Edge Repair in Mitral Regurgitation
In-Vivo Patient-Specific Optimization of Transcatheter-Edge-to-Edge Repair in Mitral Regurgitation
批准号:
10751196
负责人:
Natalie Simonian
金额:
$3.92万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2025-08-31
关键词:
Adverse effectsAgeBehaviorBiological MarkersBiomechanicsBlindedBloodCalibrationCardiomyopathiesCardiovascular DiseasesCharacteristicsClinicalClinical TrialsClipComplexComputer ModelsContractsDataData SetDatabasesDiseaseElementsEtiologyExtravasationGeometryGrowthHeartHeterogeneityHumanImageIschemiaLeadLeft atrial structureLeft ventricular structureLinkLungMethodsMitral ValveMitral Valve InsufficiencyMyocardial InfarctionNatureOperative Surgical ProceduresOutcomePatient imagingPatient-Focused OutcomesPatientsPopulationPositioning AttributePostoperative PeriodProceduresProcessPrognostic FactorPropertyRaceRadialRecurrenceReportingSelection for TreatmentsShapesStressTechniquesTestingTherapeuticThree-Dimensional EchocardiographyTimeTissuesTreatment EfficacyTreatment outcomeVariantWorkcase-by-case basisclinical imagingcohortcomputational pipelinesexperienceimaging modalityimprovedin silicoin vivoinsightmechanical loadnoveloutcome predictionpatient populationpatient stratificationpostoperative statepre-doctoralpreoperative staterepair modelrepairedsexsimulationsuccessthree-dimensional modelingtreatment optimizationtreatment strategytrial comparing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Mitral regurgitation (MR) is a prevalent and deadly disease characterized by the inability of the mitral
valve (MV) leaflets to coapt properly, permitting backflow of blood from the left ventricle into the left
atrium. The etiologies of MR are complex and diverse, ranging from myxomatous degeneration of the
valvular tissue to myocardial infarction to non-ischemic cardiomyopathy. Several types of treatment are
available, but the efficacy of these interventions remains suboptimal and unpredictable. One of these
options is the relatively recent transcatheter edge-to-edge leaflet clipping technique called the MitraClip
procedure (or TEER). Though the procedure is safe, its outcomes in clinical trials, particularly compared
to other surgical and therapeutic treatments, have been highly contradictory, largely due to the
multifactorial nature of MR. Therefore, it is clear that a predictive approach to treatment selection that
accounts for patient specific variations in MV shape and deformation is necessary to optimize long-
term patient outcomes. Our group has developed a noninvasive, image-based method for in vivo MV
strain estimation which allows us to quantify MV shape and deformation directly from clinically available
imaging data. We have also previously demonstrated that this technique can be used to identify
predictive, presurgical factors of repair efficacy for ischemic MR patients undergoing undersized ring
annuloplasty. However, previous work by our lab and others has focused on limited subsets of MR
patients; in order to develop a comprehensive treatment selection guide, simulations must be grounded
in a robust understanding of the altered MV biomechanical state in the full range of MR etiologies.
Furthermore, the effects of the highly non-physiological focal stress of the MitraClip on the immediate
and long-term shape and deformation of the MV leaflets remains almost completely unknown. We will
additionally develop a fully predictive finite element simulation of the TEER procedure in order to
preoperatively test various MitraClip scenarios directly on a 3D model of the patient's MV apparatus,
use our understanding of the MV functional state to predict the 12-month outcomes of each
configuration, and select the most optimal option. Therefore, in this study, we aim to (1) establish the
pre-operative state of the MV across the MR spectrum and (2) elucidate and predict the consequences
of the MitraClip on MV leaflet geometry, behavior, and remodeling in order to explain and ultimately
predict the outcomes of this treatment in a patient-specific and quantitative manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: